McShane - TB Vaccine Development PDF of lecture/McShane - TB... · In all environmental...

6
Recording date: Jul 2014

Transcript of McShane - TB Vaccine Development PDF of lecture/McShane - TB... · In all environmental...

Page 1: McShane - TB Vaccine Development PDF of lecture/McShane - TB... · In all environmental mycobacteria Doesn't interfere with new diagnostic tests BCG - MVA85A regimen Global TB Vaccine

   Recording  date:  Jul  2014

Page 2: McShane - TB Vaccine Development PDF of lecture/McShane - TB... · In all environmental mycobacteria Doesn't interfere with new diagnostic tests BCG - MVA85A regimen Global TB Vaccine
Page 3: McShane - TB Vaccine Development PDF of lecture/McShane - TB... · In all environmental mycobacteria Doesn't interfere with new diagnostic tests BCG - MVA85A regimen Global TB Vaccine
Page 4: McShane - TB Vaccine Development PDF of lecture/McShane - TB... · In all environmental mycobacteria Doesn't interfere with new diagnostic tests BCG - MVA85A regimen Global TB Vaccine
Page 5: McShane - TB Vaccine Development PDF of lecture/McShane - TB... · In all environmental mycobacteria Doesn't interfere with new diagnostic tests BCG - MVA85A regimen Global TB Vaccine
Page 6: McShane - TB Vaccine Development PDF of lecture/McShane - TB... · In all environmental mycobacteria Doesn't interfere with new diagnostic tests BCG - MVA85A regimen Global TB Vaccine

TB Vaccine R&D Roadmap Background Document

TB Vaccine R&D Roadmap Background Document

South Africa - Republic of Agricultural Biotechnology ......Aug 12, 2013  · Triclinium AERAS-402 Vaccine TB AERAS-422 Vaccine TB VPM1002 Vaccine TB OncoVEX Ad26.ENVA.01 & Ad35-ENV

South Africa - Republic of Agricultural Biotechnology ......Aug 12, 2013  · Triclinium AERAS-402 Vaccine TB AERAS-422 Vaccine TB VPM1002 Vaccine TB OncoVEX Ad26.ENVA.01 & Ad35-ENV

TB Vaccine Clinical Pipeline: Review of Candidates in ... · WHO Global TB Report 2016 •10.4 million incident TB cases –5.9 million (56%) men ... treatment of active TB and latent

TB Vaccine Clinical Pipeline: Review of Candidates in ... · WHO Global TB Report 2016 •10.4 million incident TB cases –5.9 million (56%) men ... treatment of active TB and latent

TB Vaccine Development Pathway

TB Vaccine Development Pathway

McShane Hastings pp33-48

McShane Hastings pp33-48

Robert Koch’s “Therapeutic TB vaccine” 1890: Purified Tuberculin Protein

Robert Koch’s “Therapeutic TB vaccine” 1890: Purified Tuberculin Protein

© 2004 Aeras Global TB Vaccine Foundation Introduction to Clinical Research Clinical Research Practice 1.

© 2004 Aeras Global TB Vaccine Foundation Introduction to Clinical Research Clinical Research Practice 1.

TB Vaccine Stakeholder Meeting and Luncheon - Aeras€¦ · and ensure global market access ... • Inducing specific T cell functionality ... 46 Sources: 1WHO TB Surveillance Report,

TB Vaccine Stakeholder Meeting and Luncheon - Aeras€¦ · and ensure global market access ... • Inducing specific T cell functionality ... 46 Sources: 1WHO TB Surveillance Report,

The role of the Childhood TB Subgroup in vaccine research Gunnar Bjune TB in the 21st Century Consortium.

The role of the Childhood TB Subgroup in vaccine research Gunnar Bjune TB in the 21st Century Consortium.

© 2004 Aeras Global TB Vaccine Foundation Intermediate Clinical Research Clinical Research Practice 2.

© 2004 Aeras Global TB Vaccine Foundation Intermediate Clinical Research Clinical Research Practice 2.

Accelerating Clinical Trials for Vaccine Development Clinical Trials for Vaccine Development Missing Vaccines •The Big Three: •HIV / AIDS •Malaria •improved TB • Viruses

Accelerating Clinical Trials for Vaccine Development Clinical Trials for Vaccine Development Missing Vaccines •The Big Three: •HIV / AIDS •Malaria •improved TB • Viruses

Partnerships in TB Vaccine Research & Development

Partnerships in TB Vaccine Research & Development

Use of Nonhuman Primates in TB vaccine research

Use of Nonhuman Primates in TB vaccine research

Kasus 3 - Mcshane

Kasus 3 - Mcshane

Approaches to TB Vaccine Development Peg Willingham Aeras Global TB Vaccine Foundation Beyond BCG: Towards an Effective New Vaccine for TB All Party Parliamentary.

Approaches to TB Vaccine Development Peg Willingham Aeras Global TB Vaccine Foundation Beyond BCG: Towards an Effective New Vaccine for TB All Party Parliamentary.

Future peptide vaccine for TB endemic regions: Challenges ... · Vaccine candidate with both prophylactic and therapeutic ... Which peptide to choose? Is promiscuous peptide right

Future peptide vaccine for TB endemic regions: Challenges ... · Vaccine candidate with both prophylactic and therapeutic ... Which peptide to choose? Is promiscuous peptide right

The Rational for a TB Vaccine

The Rational for a TB Vaccine

EIB Advisory Considerations Global TB Vaccine Partnership

EIB Advisory Considerations Global TB Vaccine Partnership

THE H1/H56 TB SUBUNIT VACCINE - AN UPDATE€¦ · THE H1/H56 TB SUBUNIT VACCINE - AN UPDATE. ... Phase IIa - Safety in TB patients ... Joshua Woodworth Thomas Lindenstrøm

THE H1/H56 TB SUBUNIT VACCINE - AN UPDATE€¦ · THE H1/H56 TB SUBUNIT VACCINE - AN UPDATE. ... Phase IIa - Safety in TB patients ... Joshua Woodworth Thomas Lindenstrøm

Tb Vaccine

Tb Vaccine